Grades the severity of cardiogenic shock from stage A (at risk) to stage E (extremis) from the bedside exam, biochemical markers, hemodynamics and the response to treatment, following the 2022 SCAI expert consensus update.
How to read the result
The result is the stage the ticked findings are most consistent with, with the findings that put it there. Staging is a clinical judgment: repeat it as the patient changes. In the 2022 update, improving by even one stage is a strong favorable sign, and staying put or getting worse an unfavorable one.
| Stage | Meaning | Hospital mortality, one cardiac ICU cohort |
|---|
| A, at risk | Acute cardiac problem (large MI, acute or acute-on-chronic heart failure) without signs of shock | 3.0% |
| B, beginning | Relative hypotension or tachycardia with preserved perfusion | 7.1% |
| C, classic | Hypoperfusion needing a drug or device beyond fluids | 12.4% |
| D, deteriorating | Initial support fails to restore perfusion | 40.4% |
| E, extremis | Actual or impending circulatory collapse, including CPR in progress | 67.0% |
Mortality is the unadjusted hospital mortality of all cardiac ICU admissions at one center (10,004 Mayo Clinic patients, 2007-2015), staged retrospectively from admission data by the 2019 criteria (Jentzer 2019). The arrest modifier (A) applies after a cardiac arrest with coma: not following commands, or a Glasgow Coma Scale below 9. A brief arrest with full neurologic recovery does not count. Mortality was higher after cardiac arrest at every stage (adjusted odds ratio 3.99 in the same cohort).
Scoring
| Stage | Findings that place a patient here (paraphrased from the 2022 update) |
|---|
| B | SBP below 90 mmHg, MAP below 60 mmHg or a fall of more than 30 mmHg from baseline; heart rate 100/min or faster; raised jugular venous pressure or rales in the lung fields; a low cardiac index, high PCWP or extensive rales with perfusion preserved |
| C | Any sign of hypoperfusion (cold, clammy or mottled skin, slow capillary refill, acute change in mental status, urine output below 30 mL/h, lactate 2 mmol/L or more, creatinine risen to 1.5 times baseline or more or by 0.3 mg/dL or more, rising liver enzymes) or the need for a vasoactive drug or device; cardiac index below 2.2 L/min/m2, PCWP above 15 mmHg and extensive rales support it |
| D | A stage C finding plus failure of the initial therapy after a period on it: hypoperfusion not improving or worsening, lactate rising and still above 2 mmol/L, escalating doses, or another drug or device added |
| E | Near-pulselessness or circulatory collapse, multiple defibrillations, CPR in progress, profound hypotension despite maximal support or vasopressor boluses, or perfusion not restored despite several drugs or devices; lactate 8 mmol/L or more is typical, and severe acidosis (pH below 7.2, base deficit above 10 mEq/L) may be present |
The highest stage with a ticked finding is shown, with two rules from the 2022 update. Stage D findings count only alongside a stage C finding, and needing a second drug soon after presentation can still be stage C, since stage D needs time on the initial therapy. At the bedside, stage E means cardiovascular collapse or CPR in progress, so a lactate of 8 mmol/L or more or severe acidosis without those signs gives at least stage C, with a note.
Validation
SCAI proposed the classification in 2019 and updated it in 2022 after validation studies in cardiogenic shock with and without acute MI, cardiac ICU patients and out-of-hospital cardiac arrest, which consistently linked higher stages with higher mortality. In the Mayo Clinic cohort, each stage above A raised adjusted hospital mortality (odds ratios 1.53 to 6.80), and cardiac arrest added independent risk (odds ratio 3.99). In 1,055 patients with infarct-related shock from CULPRIT-SHOCK, the classification picked out stage E well but separated stages C and D poorly. The stage measures shock severity, not overall risk: age, cause, phenotype and comorbidities change the outlook within each stage. SCAI published a further update in November 2026; this calculator follows the 2022 criteria.
References
- Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies. J Am Coll Cardiol. 2022;79(9):933-946. PMID 35115207
- Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheter Cardiovasc Interv. 2019;94(1):29-37. PMID 31104355
- Jentzer JC, van Diepen S, Barsness GW, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol. 2019;74(17):2117-2128. PMID 31548097
- Freund A, Pöss J, de Waha-Thiele S, et al. Comparison of risk prediction models in infarct-related cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2021;10(8):890-897. PMID 34529043
- Baran DA, Naidu SS, Jentzer JC, et al. 2026 SCAI SHOCK classification expert consensus update: refined staging and incorporation of clinical phenotypes and patient populations. J Soc Cardiovasc Angiogr Interv. 2026:105736. doi 10.1016/j.jscai.2026.105736